FDA Adverse Event Injury Summary report: N

LAP-BAND AP ADJUSTABLE GASTRIC BANDING SYSTEM (LARGE)

MDR report key: 1841325 · Received September 13, 2010

Report

Report Number
2024601-2010-00736
Event Type
Injury
Date Received
September 13, 2010
Date of Event
September 21, 2009
Report Date
July 26, 2010
Manufacturer
ALLERGAN
Product Code
LTI
PMA / PMN Number
P000008
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

TAPER II. (B)(4). THE ACCESS PORT CONNECTOR ASSOCIATED WITH THIS REPORT HAS NOT BEEN RETURNED WITH THE LAP-BAND SYSTEM BY THE RPTR. BASED UPON THE MODEL NUMBER AND IMPLANT DATE PROVIDED BY THE RPTR, THE CONNECTOR TYPE IS ASSUMED TO BE A TAPER II. ALLERGAN HAS REC'D THE PRODUCT; HOWEVER, THE ANALYSIS HAS NOT BEEN COMPLETED AT THIS TIME. REFLUX IS A SURGICAL/PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT. THE RPTR OF THE COMPLAINT WAS ASKED TO INDICATE THE PRODUCT SERIAL NUMBER. THE INFO HAS NOT YET BEEN REC'D BY ALLERGAN. DEVICE LABELING ADDRESSES THE POSSIBLE OUTCOME OF REFLUX AS FOLLOWS: "ULCERATION, GASTRITIS, GASTROESOPHAGEAL REFLUX, HEARTBURN, GAS BLOAT, DYSPHAGIA, DEHYDRATION, CONSTIPATION AND WEIGHT REGAIN HAVE BEEN REPORTED AFTER GASTRIC RESTRICTION PROCEDURES."

Description of Event or Problem · 1

REC'D A VOICEMAIL MESSAGE FROM HEALTH PROFESSIONAL REQUESTING A RETURN KIT FOR AN EXPLANTED DEVICE. IN THE MESSAGE, HEALTH PROFESSIONAL SAID THEY HAVE A LAP-BAND TO RETURN TO ALLERGAN. F/U FINDINGS: PFN WAS SENT TO ALLERGAN WITH BAND. EVENT DESCRIPTION STATES: "BAND EXPLANT." FURTHER FINDINGS STATE, "WAS EXPLANTED DUE TO NOCTURNAL REFLUX. PROBLEM FIRST OBSERVED WHEN PT COME IN, [WITH WEIGHT] UP (B)(6). AFTER BAND LOOSENING DUE TO REFLUX. WAS REPLACED WITH NEW BAND."

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 LAP-BAND AP ADJUSTABLE GASTRIC BANDING SYSTEM (LARGE) LTI ALLERGAN NA NI

Patients

Seq Age Sex Outcome Treatment
1 35 YR Required Intervention